APA (7th ed.) Citation

Fastner, C., Yücel, G., Hetjens, S., Rudic, B., Schmiel, G., Toepel, M., . . . Kuschyk, J. (2022). Should HFrEF patients with NYHA class II expect benefit from CCM therapy?: Results from the MAINTAINED observational study. Clinical research in cardiology, 111(11), . https://doi.org/10.1007/s00392-022-02089-w

Chicago Style (17th ed.) Citation

Fastner, Christian, et al. "Should HFrEF Patients with NYHA Class II Expect Benefit from CCM Therapy?: Results from the MAINTAINED Observational Study." Clinical Research in Cardiology 111, no. 11 (2022). https://doi.org/10.1007/s00392-022-02089-w.

MLA (9th ed.) Citation

Fastner, Christian, et al. "Should HFrEF Patients with NYHA Class II Expect Benefit from CCM Therapy?: Results from the MAINTAINED Observational Study." Clinical Research in Cardiology, vol. 111, no. 11, 2022, https://doi.org/10.1007/s00392-022-02089-w.